Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.

Abstract

Pediatric anaplastic large-cell lymphoma (ALCL), which is characterized by strong expression of CD30, is usually responsive to multidrug chemotherapy. Brentuximab vedotin (BV) which is an anti-CD30 antibody-drug conjugate is a promising drug with effects on relapsing or refractory ALCL. However, its effects may not be sufficient for the central nervous system disease. The authors herein reported an 11-year-old boy with ALCL that progressed as central nervous system disease receiving intensive induction chemotherapy has achieved and maintained remission by BV and high-dose methotrexate administrated alternately. Alternate therapy with high-dose methotrexate may complement these shortcomings of BV to provide safe treatment without worsening adverse events.

• Authors: Takuro Mitsunobu, Takuro Nishikawa, Masaki Kusuda, Shunsuke Nakagawa, Yuichi Kodama, Yasuhiro Okamoto, Yoshifumi Kawano
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 42 Issue 6 Pg. e456-e458 (08 2020) ISSN: 1536-3678 [Electronic] United States
• PMID: 31274669 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Brentuximab Vedotin
• Methotrexate

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Brentuximab Vedotin (administration & dosage)
• Central Nervous System Diseases (complications, drug therapy, pathology)
• Child
• Humans
• Lymphoma, Large-Cell, Anaplastic (complications, drug therapy, pathology)
• Male
• Methotrexate (administration & dosage)
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Prognosis